Gene editing (GE) therapies hold immense promise for treating a myriad of diseases. Like most novel products, their development and regulatory approval necessitate careful consideration of critical ...
Gene editing platforms like CRISPR-Cas9 that rely on nuclease activity introduce effective modifications, however, they arise from double strand DNA breaks (DSBs) introduced by the nuclease that can ...
Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children’s to present EDIT-301 clinical data at ASH on Monday, ...
CRISPR/Cas gene editing technology has rapidly evolved over the last decade. Its versatility extends from creating targeted research-use disease models in cells and animals, to high-throughput ...
New trends and challenges are being identified as more cell and gene therapy institutions move toward clinical trials and into commercialization. Closed manufacturing systems are designed to minimize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results